Dr. Olatunji Alese
Claim this profileEmory University Hospital/Winship Cancer Institute
Studies Tumors
Studies Solid Tumors
14 reported clinical trials
38 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
MMR positive
2Solid Tumors
Stage IV
Stage III
RECIST
Affiliated Hospitals
Clinical Trials Olatunji Alese is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
More about Olatunji Alese
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Olatunji Alese has experience with
- Regorafenib
- Cetuximab
- Irinotecan
- Dostarlimab
- Nab-paclitaxel
- Gemcitabine
Breakdown of trials Olatunji Alese has run
Tumors
Solid Tumors
Adenocarcinoma
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Olatunji Alese specialize in?
Olatunji Alese focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Olatunji Alese currently recruiting for clinical trials?
Yes, Olatunji Alese is currently recruiting for 5 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Olatunji Alese has studied deeply?
Yes, Olatunji Alese has studied treatments such as Regorafenib, Cetuximab, Irinotecan.
What is the best way to schedule an appointment with Olatunji Alese?
Apply for one of the trials that Olatunji Alese is conducting.
What is the office address of Olatunji Alese?
The office of Olatunji Alese is located at: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory University Hospital/Winship Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.